California 2019-2020 Regular Session

California Assembly Bill AR32 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION House Resolution No. 32Introduced by Assembly Member MullinMay 01, 2019 Relative to Tardive Dyskinesia Awareness Week. LEGISLATIVE COUNSEL'S DIGESTHR 32, as introduced, Mullin. Digest KeyBill TextWHEREAS, Many people with serious, chronic mental illness, such as schizophrenia and other schizoaffective disorders, bipolar disorder, or severe depression, require treatment with medications that work as dopamine receptor blocking agents (DRBAs), including antipsychotics; andWHEREAS, While ongoing treatment with these medications can be very helpful, and even lifesaving, for many people, it can also lead to Tardive Dyskinesia (TD); andWHEREAS, Many people who have gastrointestinal disorders, including gastroparesis, nausea, and vomiting, also require treatment with DRBAs; andWHEREAS, Treatment of gastrointestinal disorders with DRBAs can be very helpful, but for many patients can lead to TD; andWHEREAS, TD is a movement disorder that is characterized by random, involuntary, and uncontrolled movements of different muscles in the face, trunk, and extremities. In some cases, people may experience movement of the arms, legs, fingers, and toes. In some cases, it may affect the tongue, lips, and jaw. In other cases, symptoms may include swaying movements of the trunk or hips and may impact the muscles associated with walking, speech, eating, and breathing; andWHEREAS, TD can develop months, years, or decades after a person starts taking DRBAs, and even after they have discontinued use of those medications. Not everyone who takes a DRBA develops TD, but if it develops it is often permanent; andWHEREAS, Common risk factors for TD include advanced age and alcoholism or other substance abuse disorders. Postmenopausal women and people with a mood disorder are also at higher risk of developing TD; andWHEREAS, A person is at higher risk for TD after taking DRBAs for three months or longer, but the longer the person is on these medications, the higher the risk of developing TD; andWHEREAS, Studies suggest that the overall risk of developing TD following prolonged exposure to DRBAs is between 10 and 30 percent; andWHEREAS, It is estimated that over 60,000 Californians suffer from TD; andWHEREAS, Years of difficult and challenging research have resulted in recent scientific breakthroughs, with two new treatments for TD approved by the United States Food and Drug Administration. TD is often unrecognized and patients suffering from the illness are commonly misdiagnosed. Regular screening for TD in patients taking DRBA medications is recommended by the American Psychiatric Association (APA); andWHEREAS, Patients who take DRBAs should be regularly evaluated by their health care providers to ensure that any signs of TD are recognized. Health care providers should use a rating scale recommended by the APA; andWHEREAS, Patients suffering from TD often suffer embarrassment due to abnormal and involuntary movements, which leads them to withdraw from society and increasingly isolate themselves as the disease progresses; andWHEREAS, The caregivers of patients with TD face many challenges and are often responsible for the overall care of the TD patient; now, therefore, be itResolved by the Assembly of the State of California, That the Assembly proclaims the week of May 6, 2019, as Tardive Dyskinesia Awareness Week, with the goal of raising awareness of this potentially debilitating disease; and be it furtherResolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
2	2
3	3	CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION House Resolution No. 32Introduced by Assembly Member MullinMay 01, 2019 Relative to Tardive Dyskinesia Awareness Week. LEGISLATIVE COUNSEL'S DIGESTHR 32, as introduced, Mullin. Digest Key
4	4
5	5
6	6
7	7
8	8
9	9	CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION
10	10
11	11	House Resolution No. 32
12	12
13	13	Introduced by Assembly Member MullinMay 01, 2019
14	14
15	15	Introduced by Assembly Member Mullin
16	16	May 01, 2019
17	17
18	18	Relative to Tardive Dyskinesia Awareness Week.
19	19
20	20	LEGISLATIVE COUNSEL'S DIGEST
21	21
22	22	## LEGISLATIVE COUNSEL'S DIGEST
23	23
24	24	HR 32, as introduced, Mullin.
25	25
26	26
27	27
28	28	## Digest Key
29	29
30	30	## Bill Text
31	31
32	32	WHEREAS, Many people with serious, chronic mental illness, such as schizophrenia and other schizoaffective disorders, bipolar disorder, or severe depression, require treatment with medications that work as dopamine receptor blocking agents (DRBAs), including antipsychotics; and
33	33
34	34	WHEREAS, While ongoing treatment with these medications can be very helpful, and even lifesaving, for many people, it can also lead to Tardive Dyskinesia (TD); and
35	35
36	36	WHEREAS, Many people who have gastrointestinal disorders, including gastroparesis, nausea, and vomiting, also require treatment with DRBAs; and
37	37
38	38	WHEREAS, Treatment of gastrointestinal disorders with DRBAs can be very helpful, but for many patients can lead to TD; and
39	39
40	40	WHEREAS, TD is a movement disorder that is characterized by random, involuntary, and uncontrolled movements of different muscles in the face, trunk, and extremities. In some cases, people may experience movement of the arms, legs, fingers, and toes. In some cases, it may affect the tongue, lips, and jaw. In other cases, symptoms may include swaying movements of the trunk or hips and may impact the muscles associated with walking, speech, eating, and breathing; and
41	41
42	42	WHEREAS, TD can develop months, years, or decades after a person starts taking DRBAs, and even after they have discontinued use of those medications. Not everyone who takes a DRBA develops TD, but if it develops it is often permanent; and
43	43
44	44	WHEREAS, Common risk factors for TD include advanced age and alcoholism or other substance abuse disorders. Postmenopausal women and people with a mood disorder are also at higher risk of developing TD; and
45	45
46	46	WHEREAS, A person is at higher risk for TD after taking DRBAs for three months or longer, but the longer the person is on these medications, the higher the risk of developing TD; and
47	47
48	48	WHEREAS, Studies suggest that the overall risk of developing TD following prolonged exposure to DRBAs is between 10 and 30 percent; and
49	49
50	50	WHEREAS, It is estimated that over 60,000 Californians suffer from TD; and
51	51
52	52	WHEREAS, Years of difficult and challenging research have resulted in recent scientific breakthroughs, with two new treatments for TD approved by the United States Food and Drug Administration. TD is often unrecognized and patients suffering from the illness are commonly misdiagnosed. Regular screening for TD in patients taking DRBA medications is recommended by the American Psychiatric Association (APA); and
53	53
54	54	WHEREAS, Patients who take DRBAs should be regularly evaluated by their health care providers to ensure that any signs of TD are recognized. Health care providers should use a rating scale recommended by the APA; and
55	55
56	56	WHEREAS, Patients suffering from TD often suffer embarrassment due to abnormal and involuntary movements, which leads them to withdraw from society and increasingly isolate themselves as the disease progresses; and
57	57
58	58	WHEREAS, The caregivers of patients with TD face many challenges and are often responsible for the overall care of the TD patient; now, therefore, be it
59	59
60	60	Resolved by the Assembly of the State of California, That the Assembly proclaims the week of May 6, 2019, as Tardive Dyskinesia Awareness Week, with the goal of raising awareness of this potentially debilitating disease; and be it further
61	61
62	62	Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.